Staphylococcus aureus in continuous culture: A tool for the rational design of antibiotic treatment protocols

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Udekwu, Klas I ^a,b   Levin, Bruce R ^a  

^a EMORY UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL CLEARANCE; BACTERIAL VIABILITY; BACTERIOPLANKTON; BACTERIUM ADHERENCE; BACTERIUM CULTURE; CELL DENSITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTINUOUS CULTURE; DRUG EFFECT; DRUG EXPOSURE; EVALUATION RESEARCH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 84864106124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038866     Document Type: Article

References (53)

1. Drusano GL, (2007) Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 45: S89-95.
2. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, et al. (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44: 79-86.
3. Craig W, Andes D, (1996) Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 15: 255-259.
4. Andes D, Anon J, Jacobs MR, Craig WA, (2004) Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 24: 477-502.
5. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, et al. (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37: 1073-1081.
6. Andes D, Craig W, Nielsen LA, Kristensen HH, (2009) In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model. Antimicrob Agents Chemother 53: 3003-3009.
7. Safdar N, Andes D, Craig WA, (2004) In Vivo Pharmacodynamic Activity of Daptomycin. Antimicrob Agents Chemother 48: 63-68.
8. Mouton JW, Punt N, (2001) Use of the t & MIC to choose between different dosing regimens of beta-lactam antibiotics. J Antimicrob Chemother 47: 500-501.
9. Baudoux P, Bles N, Lemaire S, Mingeot-Leclercq M-P, Tulkens PM, et al. (2007) Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 59: 246-253.
10. Gillespie EL, Kuti JL, Nicolau DP, (2005) Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol 1: 351-361.
11. Institute CaLS (2005) Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement.
12. EUCAST (2000) Definitive Document E. Def 2.1. Determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 6: 570-572.
13. Mouton JW, (2002) Breakpoints: current practice and future perspectives. Int J Antimicrob Agents 19: 323-331.
14. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, et al. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48: 3670-3676.
15. Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR, (2009) Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63: 745-757.
16. Soriano F, Ponte C, Santamaria M, Jimenez-Arriero M, (1990) Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. J Antimicrob Chemother 25: 621-627.
17. Davey PG, Barza M, (1987) The inoculum effect with gram-negative bacteria in vitro and in vivo. J Antimicrob Chemother 20: 639-644.
18. Soriano F, Ponte C, (2009) Comment on: Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63: 1301.
19. Amsterdam D, (2005) Susceptibility Testing of Antimicrobials in Liquid Media. In: Lorian V, editors. pp. 61-144 editor. Antibiotics in Laboratory Medicine. 5 ed. Baltimore: Lippincott Williams & Wilkins.
20. Craig WA, (1993) Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 31 Suppl D pp. 149-158.
21. Andrew JH, Wale MC, Wale LJ, Greenwood D, (1987) The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother 20: 213-221.
22. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A, (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132: 1297-1304.
23. Bigger J, (1944) Treatment of Staphylococcal infections with penicillin. The Lancet 2497-500.
24. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S, (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622-1625.
25. Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, et al. (2005) Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49: 1483-1494.
26. Lewis K, (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48-56.
27. Stewart PS, (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292: 107-113.
28. Fux CA, Costerton JW, Stewart PS, Stoodley P, (2005) Survival strategies of infectious biofilms. Trends Microbiol 13: 34-40.
29. Patel R, (2005) Biofilms and antimicrobial resistance. Clin Orthop Relat Res pp. 41-47.
30. Thwaites GE, Gant V, (2011) Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nat Rev Microbiol 9: 215-222.
31. Lowdin E, Odenholt I, Cars O, (1998) In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 42: 2739-2744.
32. MacKenzie FM, Gould IM, (1993) The post-antibiotic effect. J Antimicrob Chemother 32: 519-537.
33. Rang C, Midtvedt T, Molin S, Chao L, (2001) Chemostat modeling of Escherichia coli persistence in conventionalized mono-associated and streptomycin-treated mice. Canadian Journal of Microbiology 47: 86-90.
34. Bonapace CR, Friedrich LV, Bosso JA, White RL, (2002) Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob Agents Chemother 46: 3574-3579.
35. Odenholt I, Lowdin E, Cars O, (2003) In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Clinical Microbiology and Infection 9: 930-937.
36. Odenholt I, Lowdin E, Cars O, (2007) Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 51: 3311-3316.
37. Leuthner KD, Cheung CM, Rybak MJ, (2006) Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 338-343.
38. Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, et al. (1998) Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 42: 1105-1109.
39. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL, (1994) Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 38: 1386-1391.
40. Brown MR, Collier PJ, Gilbert P, (1990) Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies. Antimicrob Agents Chemother 34: 1623-1628.
41. Gilbert P, Allison DG, Evans DJ, Handley PS, Brown MR, (1989) Growth rate control of adherent bacterial populations. Appl Environ Microbiol 55: 1308-1311.
42. Anwar H, Dasgupta M, Lam K, Costerton JW, (1989) Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother 24: 647-655.
43. Odenholt I, Cars T, Lowdin E, (2000) Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 46: 35-43.
44. Levin BR, Udekwu KI, (2010) The Population Dynamics of Antibiotic Treatment: A Mathematical Model and Hypotheses for Time-Kill and Continuous Culture Experiments. Antimicrob Agents Chemotherapy 54: 3414-3426.
45. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K, (2004) Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 186: 8172-8180.
46. Lewis K, (2000) Programmed death in bacteria. Microbiol Mol Biol Rev 64: 503-514.
47. Anwar H, Strap JL, Costerton JW, (1992) Eradication of biofilm cells of Staphylococcus aureus with tobramycin and cephalexin. Can J Microbiol 38: 618-625.
48. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC, (2009) Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 31: 1936-1945.
49. Skiest DJ, (2006) Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44: 655-656.
50. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, et al. (2010) D-amino acids trigger biofilm disassembly. Science 328: 627-629.
51. Lopez D, Kolter R, (2010) Functional microdomains in bacterial membranes. Genes Dev 24: 1893-1902.
52. Allison KR, Brynildsen MP, Collins JJ, (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216-220.
53. Sillankorva S, Oliveira R, Vieira MJ, Azeredo J, (2008) Real-time quantification of Pseudomonas fluorescens cell removal from glass surfaces due to bacteriophage varphiS1 application. J Appl Microbiol 105: 196-202.